한글목차

항체 생산 시장은 2022년에 123억 달러로 평가되었고, 2023년부터 2032년까지 CAGR은 9.1%로 성장을 지속할 전망이며, 2032년에는 294억 달러에 이를 것으로 예측되고 있습니다. 항체 생산이란, B세포라 불리는 면역계의 특수한 세포가 세균, 바이러스, 기타 병원체 등의 이물질의 존재에 반응하여 항체를 생산하는 공정을 말합니다. 항체는 면역글로불린으로도 알려진 Y자형 단백질로, 병원체의 표면에 존재하는 특이적인 분자인 항원을 특이적으로 인식하고 결합합니다.

항체 생산의 단계는 B세포가 그의 특정 수용체와 일치하는 항원을 만나는 것으로 시작됩니다. 이 만남이 B세포의 활성화와 증식의 방아쇠가 되어 클론으로 알려진 동일한 B세포가 대량으로 생산됩니다. 활성화된 B세포는 그 후 항체 생산 공장인 형질 세포로 분화됩니다. 혈장세포는 대량의 항체를 혈류나 기타 체액 중에 분비해, 거기서 병원체와 결합하여 중화하거나, 다른 면역 세포에 의한 파괴의 표시가 되기도 합니다.

항체 생산 시장의 성장을 가속하는 요인으로는 표적 요법을 필요로 하는 만성 질환 증가, 생산 효율과 확대성을 높이는 생명공학의 진보, 치료 및 연구 용도에서의 단클론항체 수요 증가, 항체 기반의 연구 개발을 촉진하는 정부의 지원책을 들 수 있습니다. 게다가 바이오의약품 업계는 연구개발에 대한 투자 증가와 생물제제 기반 치료법의 채용 증가에 의해 급속한 성장을 이루고 있습니다. 항체는 바이오 의약품의 대부분을 차지하고 있으며, 항체 생산 기술과 서비스 수요를 견인하고 있습니다.

또한, 바이오테크놀러지 연구개발의 촉진을 목적으로 한 정부의 대처나, 바이오의약품 기업 및 학술기관에 대한 자금 원조가, 항체 생산 시장의 혁신과 성장을 가속하고 있습니다. 관민 파트너십과 보조금 제도는 항체 관련 연구 및 상업화 확대에 기여하고 있습니다. 예를 들어, 2023년에는 항체 생산에 관한 정부의 이니셔티브으로서 HIV 감염으로부터 자신을 보호하기 위한 광범위한 중화 HIV 항체 등 면역 반응의 확립과 유지의 메커니즘을 밝히기 위한 연구를 지원하는 미국 국립 위생연구소(NIH)가 예정되어 있습니다. 따라서 항체 연구 및 상업화를 위한 정부 이니셔티브 증가는 시장 성장을 더욱 촉진합니다. 또한, 단클론항체(mAbs)는 높은 특이성과 효능으로 인해 다양한 치료 부문에서 널리 받아들여지고 있습니다. 승인된 단클론항체 의약품의 수가 증가하고 종양학, 면역학 및 기타 부문에서의 용도가 확대됨으로써 항체 생산 및 시약 수요가 이어지고 있습니다.

그러나 항체 개발 및 생산과 관련된 높은 비용은 항체 생산 시장의 성장에 큰 억제요인이 되었습니다. 항체 개발에는 항원 선택, 하이 브리 도마 및 파지 디스플레이 라이브러리 제작, 항체 스크리닝, 최적화 등 일련의 복잡하고 자원 집약적인 공정이 필요합니다. 이러한 공정에는 전문 지식, 고급 장비 및 광범위한 실험실 자원이 필요하며 개발 비용을 밀어 올리고 있습니다. 게다가, 치료용 항체의 생산은 대규모 세포 배양, 정제, 제형화 및 품질 관리의 공정을 포함하며, 이들 모두는 생산 비용의 상승을 초래하여 시장 성장을 억제할 수 있습니다. 한편, 바이오의약품 산업의 성장과 연구개발 투자 증가는 시장 성장 기회가 되고 있습니다.

항체 생산 시장은 제품, 공정, 최종 사용자, 지역에 따라 구분됩니다. 제품별로 시장은 장비와 소모품으로 이분됩니다. 장비 부문은 또한 생물반응기, 크로마토그래피 시스템, 여과 시스템으로 분류됩니다. 공정별로 시장은 업스트림 공정과 다운스트림 공정으로 나뉩니다. 최종 사용자별로는 제약 및 바이오테크놀러지 기업, CRO 및 CDMO 등으로 분류됩니다.

이해관계자를 위한 주요 이점

• 본 보고서에서는 2022년부터 2032년까지 항체 생산 시장 분석 시장 부문, 현재의 동향, 추정 및 동향, 역학을 정량적으로 분석하여 일반적인 항체 생산 시장의 기회를 특정합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 기재하고 있습니다.
• Porter's Five Forces 분석은 이해관계자들이 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자 및 공급업체의 잠재력을 보여줍니다.
• 항체 생산 시장의 세분화를 상세하게 분석함으로써 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 공헌도에 따라 매핑됩니다.
• 시장 진출기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 진출기업의 현재 포지션을 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계의 항체 생산 시장 동향, 주요 기업, 시장 부문, 용도 부문 및 시장 성장 전략 분석이 포함되어 있습니다.

본 보고서의 가능한 맞춤설정(별도 비용과 기간이 걸리므로, 자세한 것은 영업 담당자에게 문의해 주세요).

• 규제 가이드라인
• 고객의 관심에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석-시장 규모 및 예측
• 기업 프로파일 확대 목록
• 과거 시장 데이터
• 주요 진출기업의 상세(소재지, 연락처, 공급자 및 벤더 네트워크 등을 포함한 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회

제4장 항체 생산 시장 : 제품별

• 개요
• 기기
  • 기기 시장 : 제품별
• 소모품

제5장 항체 생산 시장 : 공정별

• 개요
• 업스트림 공정
• 다운스트림 공정

제6장 항체 생산 시장 : 최종 사용자별

• 개요
• 제약 및 바이오테크놀러지 기업
• CRO 및 CDMO
• 기타

제7장 항체 생산 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • Gcc
  • 남아프리카
  • 북아프리카
  • 기타

제8장 경쟁 구도

• 서문
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 프로파일

• Thermo Fisher Scientific Inc.
• Sartorius AG
• Cellabcdmo
• Agilent Technologies, Inc.
• Genetix Biotech Asia Pvt. Ltd.
• Cell Culture Company
• Bio-Rad Laboratories, Inc.
• TECNIC
• Merck KGaA
• Danaher Corporation

영문목차

The antibody production market was valued at $12.3 billion in 2022 and is projected to reach $29.4 billion by 2032, registering a CAGR of 9.1% from 2023 to 2032. Antibody production refers to the process by which specialized cells in the immune system, called B cells, produce antibodies in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Antibodies, also known as immunoglobulins, are Y-shaped proteins that specifically recognize and bind to antigens, which are unique molecules present on the surface of pathogens.

The process of antibody production begins when a B cell encounters an antigen that matches its specific receptor. This encounter triggers the activation and proliferation of the B cell, leading to the production of a large number of identical B cells, known as a clone. These activated B cells then differentiate into plasma cells, which are antibody-producing factories. Plasma cells secrete large quantities of antibodies into the bloodstream and other bodily fluids, where they can bind to and neutralize pathogens or mark them for destruction by other immune cells.

Factors driving the growth of the antibody production market include increase in prevalence of chronic diseases necessitating targeted therapies, advancements in biotechnology enhancing production efficiency and scalability, rising demand for monoclonal antibodies across therapeutic and research applications, and supportive government initiatives fostering research and development in antibody-based therapeutics. In addition, the biopharmaceutical industry is experiencing rapid growth due to increase in investments in research and development, as well as the rise in adoption of biologics-based therapies. Antibodies represent a significant portion of biopharmaceuticals, driving the demand for antibody production technologies and services.

Furthermore, government initiatives aimed at promoting biotechnology research and development, as well as funding support for biopharmaceutical companies and academic institutions, are fostering innovation and growth in the antibody production market. Public-private partnerships and grant programs are also contributing to the expansion of antibody-related research and commercialization efforts. For instance, in 2023, government initiatives for antibody production include the National Institutes of Health (NIH) supporting research to define mechanisms for establishing and maintaining immune responses, such as broadly neutralizing HIV antibodies to protect against HIV acquisition. Thus, rise in government initiatives for research and commercialization of antibodies further propels the market growth. Moreover, monoclonal antibodies (mAbs) have gained widespread acceptance in various therapeutic areas due to their high specificity and efficacy. The increasing number of approved monoclonal antibody drugs and their expanding applications in oncology, immunology, and other fields are driving the demand for antibody production and reagents.

However, the high costs associated with the development and production of antibodies present a significant restraint on the growth of the antibody production market. Antibody development involves a series of complex and resource-intensive processes, including antigen selection, hybridoma or phage display library generation, antibody screening, and optimization. These processes require specialized expertise, sophisticated equipment, and extensive laboratory resources, driving up development costs. Additionally, the production of therapeutic antibodies involves large-scale cell culture, purification, formulation, and quality control steps, all of which contribute to high production costs which may restrain market growth. On the other hand, the growing biopharmaceutical industry, coupled with increase in investments in research and development, presents opportunity to market growth.

The antibody production market is segmented on the basis of product, process, end user and region. By product, the market is bifurcated into instruments and consumables. The instruments segment is further categorized into bioreactors, chromatography systems, and filtration systems. By process, the market is divided into upstream processing and downstream processing. As per end user, it is segregated into pharmaceutical and biotechnology companies, CROs and CDMOs, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the antibody production market are Thermo Fisher Scientific Inc., Sartorius AG, Cellabcdmo, Agilent, Genetix Biotech Asia Pvt. Ltd., Cell Culture Company, Bio-Rad Laboratories, Inc, TECNIC, Merck KGaA, and Danaher Corporation. Key players have adopted acquisition as key developmental strategies to improve the product portfolio of the antibody production market.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody production market analysis from 2022 to 2032 to identify the prevailing antibody production market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the antibody production market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global antibody production market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By End User

• Pharmaceutical and Biotechnology Companies
• CROs and CDMOs
• Others

By Product

• Instruments
  • Type
  • Bioreactors
  • Chromatography Systems
  • Filtration Systems
• Consumables

By Process

• Upstream Processing
• Downstream Processing

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• Thermo Fisher Scientific Inc.
• Sartorius AG
• Cellabcdmo
• Agilent Technologies, Inc.
• Genetix Biotech Asia Pvt. Ltd.
• Cell Culture Company
• Bio-Rad Laboratories, Inc.
• TECNIC
• Merck KGaA
• Danaher Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Instruments
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Instruments Antibody Production Market by Type
• 4.3. Consumables
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Upstream Processing
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Downstream Processing
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Pharmaceutical and Biotechnology Companies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. CROs and CDMOs
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Product
  • 7.2.3. Market size and forecast, by Process
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Product
    • 7.2.5.1.2. Market size and forecast, by Process
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Product
    • 7.2.5.2.2. Market size and forecast, by Process
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Product
    • 7.2.5.3.2. Market size and forecast, by Process
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Product
  • 7.3.3. Market size and forecast, by Process
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Product
    • 7.3.5.1.2. Market size and forecast, by Process
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Product
    • 7.3.5.2.2. Market size and forecast, by Process
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Product
    • 7.3.5.3.2. Market size and forecast, by Process
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Product
    • 7.3.5.4.2. Market size and forecast, by Process
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Product
    • 7.3.5.5.2. Market size and forecast, by Process
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Product
    • 7.3.5.6.2. Market size and forecast, by Process
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Product
  • 7.4.3. Market size and forecast, by Process
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Product
    • 7.4.5.1.2. Market size and forecast, by Process
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Product
    • 7.4.5.2.2. Market size and forecast, by Process
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Product
    • 7.4.5.3.2. Market size and forecast, by Process
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Product
    • 7.4.5.4.2. Market size and forecast, by Process
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Product
    • 7.4.5.5.2. Market size and forecast, by Process
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Product
    • 7.4.5.6.2. Market size and forecast, by Process
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Product
  • 7.5.3. Market size and forecast, by Process
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Product
    • 7.5.5.1.2. Market size and forecast, by Process
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Product
    • 7.5.5.2.2. Market size and forecast, by Process
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Product
    • 7.5.5.3.2. Market size and forecast, by Process
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest Of La
    • 7.5.5.4.1. Market size and forecast, by Product
    • 7.5.5.4.2. Market size and forecast, by Process
    • 7.5.5.4.3. Market size and forecast, by End User
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Product
  • 7.6.3. Market size and forecast, by Process
  • 7.6.4. Market size and forecast, by End User
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Product
    • 7.6.5.1.2. Market size and forecast, by Process
    • 7.6.5.1.3. Market size and forecast, by End User
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Product
    • 7.6.5.2.2. Market size and forecast, by Process
    • 7.6.5.2.3. Market size and forecast, by End User
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Product
    • 7.6.5.3.2. Market size and forecast, by Process
    • 7.6.5.3.3. Market size and forecast, by End User
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Product
    • 7.6.5.4.2. Market size and forecast, by Process
    • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Thermo Fisher Scientific Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Sartorius AG
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Cellabcdmo
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Agilent Technologies, Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Genetix Biotech Asia Pvt. Ltd.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Cell Culture Company
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Bio-Rad Laboratories, Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. TECNIC
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Merck KGaA
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Danaher Corporation
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments